National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
Sonoma Pharmaceuticals (Nasdaq: SNOA) announced on November 13, 2025 that Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel earned the National Rosacea Society Seal of Acceptance. The Seal identifies products clinically evaluated and found unlikely to irritate sensitive rosacea skin. Reliefacyn previously earned the National Eczema Association Seal of Acceptance and the National Psoriasis Foundation Seal of Recognition, highlighting Sonoma's Microcyn-based skincare portfolio and focus on products for chronic skin conditions.
Sonoma Pharmaceuticals (Nasdaq: SNOA) ha annunciato il 13 novembre 2025 che il Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel ha ottenuto il Seal of Acceptance della National Rosacea Society. Il Seal identifica prodotti valutati clinicamente e risultati come non irritanti per la pelle sensibile affetta da rosacea. In precedenza Reliefacyn aveva ottenuto il Seal of Acceptance della National Eczema Association e il Seal of Recognition della National Psoriasis Foundation, evidenziando l'portfolio di skincare di Sonoma basato su Microcyn e l'impegno per prodotti per condizioni cutanee croniche.
Sonoma Pharmaceuticals (Nasdaq: SNOA) anunció el 13 de noviembre de 2025 que Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel obtuvo el Sello de Aceptación de la National Rosacea Society. El Sello identifica productos evaluados clínicamente y considerados poco irritantes para la piel sensible con rosácea. Reliefacyn previamente obtuvo el Sello de Aceptación de la National Eczema Association y el Sello de Reconocimiento de la National Psoriasis Foundation, destacando la cartera de cuidado de la piel basada en Microcyn de Sonoma y su enfoque en productos para condiciones cutáneas crónicas.
Sonoma Pharmaceuticals (나스닥: SNOA)가 2025년 11월 13일에 Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel가 National Rosacea Society의 수용 마크를 얻었다고 발표했습니다. 이 마크는 임상적으로 평가되어 rosacea가 있는 민감한 피부에 자극을 주지 않는 것으로 판단된 제품을 식별합니다. Reliefacyn은 이전에 National Eczema Association의 수용 마크와 National Psoriasis Foundation의 인정 마크를 얻었으며, Sonoma의 Microcyn 기반 스킨케어 포트폴리오와 만성 피부 질환에 대한 제품 집중을 강조합니다.
Sonoma Pharmaceuticals (Nasdaq: SNOA) a annoncé le 13 novembre 2025 que Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel a obtenu le Sceau d'Acceptation de la National Rosacea Society. Le Sceau identifie des produits évalués cliniquement et considérés comme peu susceptibles d'irriter la peau sensible atteinte de rosacée. Reliefacyn avait déjà obtenu le Sceau d'Acceptation de la National Eczema Association et le Sceau de Reconnaissance de la National Psoriasis Foundation, mettant en évidence le portefeuille de soins de la peau à base de Microcyn de Sonoma et son orientation vers des produits pour les affections cutanées chroniques.
Sonoma Pharmaceuticals (Nasdaq: SNOA) gab am 13. November 2025 bekannt, dass Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel das Seal of Acceptance der National Rosacea Society erhalten hat. Das Siegel kennzeichnet Produkte, die klinisch bewertet wurden und als unwahrscheinlich eingestuft wurden, die empfindliche Rosacea-Haut zu reizen. Reliefacyn hatte zuvor das Seal of Acceptance der National Eczema Association und das Seal of Recognition der National Psoriasis Foundation erhalten, was Sonamas Microcyn-basierte Hautpflegeportfolio und den Fokus auf Produkte für chronische Hauterkrankungen hervorhebt.
شركة Sonoma Pharmaceuticals (بورصة Nasdaq: SNOA) أعلنت في 13 نوفمبر 2025 أن Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel قد حصل على ختم قبول الجمعية الوطنية للروزايا. هذا الختم يحدد المنتجات التي خضعت لتقييم سريريًا وتبين أنها غير مهيجة للبشرة الحساسة المصابة بالروزايا. سابقًا حصل Reliefacyn على ختم قبول الجمعية الوطنية للإكزيما وختم الاعتراف من مؤسسة الصدفية الوطنية، مما يبرز محفظة العناية بالبشرة المعتمدة على Microcyn لدى سونوما وتركيزها على المنتجات لحالات البشرة المزمنة.
- None.
- None.
BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced that Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel has earned the National Rosacea Society (NRS) Seal of Acceptance.
The NRS introduced the Seal of Acceptance program to identify gentle skin care and cosmetic products that have been clinically tested, expertly evaluated and found to be unlikely to irritate sensitive rosacea skin - providing valuable guidance to those searching for skin care and cosmetics that may be suitable for people with rosacea.
"We are honored to receive this recognition from the National Rosacea Society," said Amy Trombly, CEO of Sonoma Pharmaceuticals. Reliefacyn, which has previously received the National Eczema Association Seal of Acceptance and the National Psoriasis Foundation Seal of Recognition, exemplifies the versatility of Sonoma's Microcyn-based products and the Company's commitment to provide safe and effective skincare solutions to the many people living with chronic skin conditions such as eczema, psoriasis and rosacea."
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "opportunities," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Microcyn® and Reliefacyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Sonoma Pharmaceuticals (SNOA) announce on November 13, 2025?
What does the National Rosacea Society Seal mean for Reliefacyn (SNOA)?
Has Reliefacyn received other dermatology endorsements prior to the NRS Seal?
Which Sonoma product earned the NRS Seal of Acceptance for rosacea in 2025?
How does the NRS Seal affect patients with rosacea looking at SNOA products?
